WO2004000038A1 - Composition and method to produce and use fermented hydrolyzed products of metabolism - Google Patents

Composition and method to produce and use fermented hydrolyzed products of metabolism Download PDF

Info

Publication number
WO2004000038A1
WO2004000038A1 PCT/US2003/018831 US0318831W WO2004000038A1 WO 2004000038 A1 WO2004000038 A1 WO 2004000038A1 US 0318831 W US0318831 W US 0318831W WO 2004000038 A1 WO2004000038 A1 WO 2004000038A1
Authority
WO
WIPO (PCT)
Prior art keywords
ingredient
group
medium
hquid
products
Prior art date
Application number
PCT/US2003/018831
Other languages
French (fr)
Inventor
Constantin V. Sobol
Yuzefa T. Sobol
Original Assignee
Technology Commercialization Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technology Commercialization Corp. filed Critical Technology Commercialization Corp.
Priority to AU2003236536A priority Critical patent/AU2003236536A1/en
Priority to CA2484639A priority patent/CA2484639C/en
Publication of WO2004000038A1 publication Critical patent/WO2004000038A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/133—Fruit or vegetables
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/20—Products from fruits or vegetables; Preparation or treatment thereof by pickling, e.g. sauerkraut or pickles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a hydrolyzed medium made by fermentation with non-pathogenic microorganisms and to the process of manufacturing and use thereof. More particularly it relates to the production of sour milk based hydrolysate, which includes the fermentation of various food ingredients and plants Using various non-pathogenic bacteria/yeast ingredients and some food-grade fungi in milk/whey or water, in its liquid form or solid dried form.
  • the medium produced by this method has physiologically beneficial effects and therapeutic activity against various diseases, including several life-threatening conditions. It can also be used in cosmetic industry for improving skin and food industry for production of dairy products, to accelerate cheese ripening and maturation, to improve the cultivation and long-term storage/preservation of viable Lactobacilli, acetic, propionic and bifidobacteria in their most active state.
  • the medium of the invention can be used as a feed supplement, for prevention and treatment of infection diseases, for growth promotion, to improve feed conversion, and to increase the yield of useful products, such as milk and eggs.
  • probiotics and prebiotics defined as "a live microbial food supplement, that beneficially effects the host animal by improving its intestinal microbial balance" and "non- digestible food ingredients that benefit the host by selectively stimulating the growth or activity of one or a number of bacteria in the colon".
  • a “symbiotic” is a combination of probiotics and prebiotics that "beneficially effects the host by improving the survival and implantation of live microbial dietary supplements in the gastrointestinal tract by selectively stimulating the growth of, and or by activating the metabolism of, one or a number of health promoting bacteria”.
  • the bacterial genera most often used in the field of probiotics are lactic acid bacteria, particularly Lactobacillus sp. and Bifidobacterium sp., these bacteria being important members of the gastrointestinal microflora of man and animals.
  • Other microorganisms used as probiotics in humans include Escherichia coli, Streptococcus sp., Enterococcus sp., Bacteroides sp., Bacillus sp., Propionibacterium sp. and various fungi.
  • probiotic microorganisms provide benefits for the internal and external surfaces of the host are numerous: competing with pathogens for food, preventing the adhesion of pathogens, antimicrobial activity, colonization resistance, various immune effects, adjuvant effect, antimutagenic effects, antigenotoxic effects, influence on enzyme activity, enzyme delivery and many others.
  • probiotics are usually targeted for use in intestinal disorders.
  • the effectiveness of probiotics has been demonstrated in the prevention and treatment of a diverse spectrum of gastrointestinal disorders, such as antibiotic-associated diarrhea, infectious bacterial and viral diarrhea, etc.
  • Some evidence suggests a role for probiotics in reducing the risk of colon cancer and the regression of tumors.
  • US Patent No. 5,308,615 by DeLoach and US Patent No. 5,478,557 by Nisbet describe a probiotic used for control of salmonella.
  • probiotics have been used therapeutically to lower cholesterol, to reduce blood pressure, treat rheumatoid arthritis, prevent cancer, and prevent or reduce the effects of atopic dermatitis, Crohn's disease, constipation as well as candidiasis and certain genitourinary tract infections such as bacterial vaginosis, vaginitis, or urinary tract infections.
  • the immunomodualting action of probiotics is helpful in reduction of allergic reactions, stimulation of phagocytosis by peripheral blood leukocytes and secretory IgA, modulation of cytokine gene expression, and many other immunological effects.
  • PCT patent No. WO 00/75284 by Olshenitsky et. al. describes a probiotic composition comprising a volatile fraction of a plant extract prepared by steam distillation and suspended microorganism such as E-coli.
  • E-coli is not exactly non-pathogenic and may cause some harm to humans in certain conditions.
  • No fermentation process of medium ingredients with bacteria is described in arriving at the end product. Rather, evaporation and condensation is used which limits the end properties of the product.
  • the product looses its antagonistic activity. Even with E-coli present, the antagonistic activity is limited because some pathogens can still grow in the medium during incubation for 24 hours.
  • Probiotic preparations currently on the market appear in various forms: in dairy products, processed into a product such as chewing gum, pills, capsules, etc., suspended in milk, freeze-dried or air-dried. They are generally composed of large numbers of one or more bacterial species that are common constituents of normal intestinal flora. Fermented milk (yogurt) and cheese are the most common foods with probiotics.
  • US Patent No. 6,228,358 by Toba describes an antioxidation product made from fermented milk. Zhang describes red rice fermentation products in the US Patent No. 6,046,022.
  • Other forms of probiotic preparations are freeze-dried or air-dried and they are available in tablets and in capsules. US Patent No.
  • Fermented cultures containing microorganisms can be used in other industries such as in cosmetics and pharmaceutical industry.
  • US Patent No. 6,270,811 by Fregonese describes a composition containing a microbial culture for skin regenerating and removing scars and wrinkles.
  • probiotics Despite their health promoting effects, probiotics have only demonstrated short-term effects. In the study of the health effects of probiotics, the incidence and/or duration of acute, short term diseases, such as diarrhea, are frequently measured. The effects of probiotic bacteria on the incidence of diseases with a protracted etiology, such as cancer or heart disease, have generally not been measured. Moreover, the effects of probiotics in life- threatening diseases, such as cancer for example, are doubtful. For probiotics to have their therapeutic effect they should be used in high doses daily and the duration of their use should be sufficiently long.
  • Lactic acid fermentation is mainly considered for dairy products. Only in some oriental foods such as cassava, mixtures of grains and legumes, have lactic acid fermentation been used for the preparation of a variety of foods made from raw materials of plant and animal origin. Processed food tends to loose a substantial part of its useful components, ferments for example, as compared to raw materials.
  • US Patent No. 5,292,511 by Kim describes the lactic acid fermentation process being used for aloe preservation, and the end product used as a health-food supplement.
  • the product and process described in the patent is limited in time (up to 96 hours) and temperature of fermentation (20-35 degrees C). At 40 degrees C the product is reported to start to decompose.
  • the inventors of the present invention believe that the fermentation process is not complete from the point of view of the instant invention.
  • US Patent No. 4,298,620 by Hagiwara proposes a fermentation process for obtaining a fermented tear grass product combining a water extract of tear grass with a Lactobacillus strain, and foods and feeds comprising that product. This patent is incorporated herein in its entirety.
  • one critical step in the process as described in this patent is heating of the tear grass before fermenting it.
  • this step effectively damages all useful ferments contained in the grass and significantly reduces its effectiveness.
  • the acidity of the end product (as measured by concentration of lactate) is low at about 0.7 to 3%.
  • Another limitation is the typical addition of sugar at the end of cultivation.
  • a heat sterilization process at 80 degree C for 40 minutes effectively destroys all live microorganisms and active ingredients, ferments for example.
  • a further object of the present invention is to provide a medium of high acidity, at least above 3% of lactate concentration (>300 T°), to promote higher vitality of those microorganisms that survive in the process of natural selection in a harsh for them acidic environment. It is noted here that lactate also plays a role of a preservative for the medium of the invention.
  • a further object is to provide a process of deep fermentation of the medium with appropriate microorganisms to cause production of metabolic products useful for human beings.
  • a new symbiotic multi-component fermented hydrolyzed medium is provided with a broad spectrum of antibacterial, antiviral and anti-fungal properties, and antagonistic activity against Protozoa.
  • the medium is produced with non-pathogenic microorgamsms, and has a high concentration of aromatic organic acids such as lactate, acetate, propionic, and other organic acids as metabolic end products of the fermentation process.
  • the medium of the invention contains live non- pathogenic microorganisms in low concentrations and the products of their intensive metabolism, thereby keeping microorganisms in their most active alive condition. It is also believed that the bacteria that remain alive have more vitality, due to the natural selection of those that can survive in the environment of high acidity.
  • Non-pathogenic microorganisms genera used are Lactobacilli, Bifidobacteria, Acetic and Propionic bacteria, yeasts and food-grade fungi.
  • the fermentation process for obtaining sour-milk hydrolyzed medium is as follows.
  • Initial ingredients include certain raw or dried vegetables, fruits, berries, offal, fish, eggs, plants, herbs, mash, sprouted grains and beans, aquatic plants, products of beekeeping, sea products, mushrooms, proteolytic ferments, chemicals and various types of sugar in the appropriate amounts.
  • the ingredients are mixed in predetermined proportions and fermented with non-pathogenic bacteria or yeasts and certain food-grade fungi in milk or whey. Fermentation can also take place in water or another appropriate biocompatible liquid.
  • the fermentation process takes 3-14 days (preferably 5-10 days) at 10-58 degrees C (preferably 32-47 degrees C) and can be carried out both aerobically and anaerobically.
  • sour milk hydrolyzed medium includes about 10 5 to 10 6 live bacteria/yeasts cells per 1.0 g of product, and comprise 1 to 30 percent by weight of protein, all essential amino acids (resulting from the partial proteolysis of proteins during culturing), organic acids, microelements and vitamins.
  • the acidity of the final product is about 300 to 900 T°, preferably between 500 to 800 T°, which corresponds to lactate concentration of between about 4.5% and 8%, and pH ranges from 1.5 to 6.5, preferably from about 3 to 4. There is no heat processing or pasteurization used in preparation of the medium.
  • the medium of the invention is not toxic and quite safe, and can be successfully utilized in high-risk patients, such as the elderly, hospitalized and the immunocompromised, including AIDS patients. No side effects were observed in babies or pregnant women in our studies.
  • the efficacy of the medium of the invention is comparable to modern pharmacological drugs (antibiotics, and antiviral and anti-fungal compounds). Moreover, this medium was effective against life-threatening diseases, such as cancer, tuberculosis, H ⁇ V/A ⁇ DS, and others, where traditional pharmacological drugs failed. No drug interaction was observed between pharmacological drugs and the medium of the present invention. On the contrary, the medium reduced considerably the side effects caused by toxic pharmacological drugs.
  • the medium can be used in food industry during the production of dairy products and cheese to accelerate cheese ripening and maturation, and as a method to cultivate and store for a long time in their most active condition Lactobacilli, acetic, propionic and bifidobacteria.
  • This medium can be used on farms as a feed supplement in animal husbandry for the prevention and treatment of infection diseases and to promote growth.
  • the medium of the invention can be used in cosmetic to improve skin condition (increasing skin elasticity and regeneration), to reduce and remove hems, scars and wrinkles, for healing burnt skin and as cream for sunburn.
  • the medium was found to possess a broad spectrum of therapeutic potential (the application was not limited to only GI tract) including reduction of DNA damage of the host cells. Boosting the immune system, immunomodulation, normalization of the number and function of blood cells, especially lymphocytes, are the most pronounced effects of this medium. These effects appear to be mainly caused by the end products of bacteria's metabolism.
  • Methods of administration of medium of the invention include: 1) the external application to the skin as a bandage to the effected organs or coating the body (rubbing it into the skin), mostly the trunk and lymph nodes, 2) inhalation, 3) administration rectally via a retention enema, 4) dripping into the nose and ears, 5) intravenous injections for reducing infections and/or for intravenous nutrition, and 6) intraperitoneal injections for reducing infections.
  • the first most important and unique aspect of the present invention is providing temperature and time conditions for the process of fermentation which ensure that at the end the fermentation is deep and complete. We found that generally at a point of about three days into the process of fermentation, most pathogens are destroyed/replaced.
  • the medium of the present invention has to be fermented for at least 3 and preferably 5 to 14 days at a temperature of at least 10 and preferably 35 to 58 degrees C to make sure that no pathogens are present. Another objective for this long time and higher temperature (as opposed to what is described in the prior art) is to make sure that microorganisms have adequate conditions to release products of their metabolism into the medium.
  • the medium has high acidity (generally, from 300 to 900 T°), low pH (from 1.5 to 6.5), high concentration of the metabolic products and relatively low concentration of microorganisms (from 10 5 to 10 6 cells/ml) as opposed to the preparations described by others.
  • the medium of the invention can be prepared following these steps: [0039] 1. Provide a food product of plant nature, wash it and cut into small pieces (dimension of pieces can vary from about 1/2 millimeter to 4 centimeters). Juice extractor may be used for such purpose. The smaller the pieces are, the better hydrolysis will be achieved. A wide variety of food or plant products may be used, for example most fruits, vegetables, berries and herbs.
  • biocompatible Hquid such as water, juice, etc. Most preferably, whey or milk or their combination may be used. Lemon, orange, or grape juice is another preferred biocompatible liquid.
  • Ambient microorganisms cause fermentation to proceed.
  • whey and milk it is a naturally present Lactobacillus.
  • appropriate strain of microorganism can be specificaUy added, Lactobacillus bulgaricus for example.
  • the fermentation endpoint is determined by measuring the acidity in Terner degree.
  • a satisfactory acidity for the medium is between 300 and 900 T°, and pH ranges between 1.5 to 6.5.
  • the strength and quality of the fermented medium of the invention depends on the number and nature of various ingredients and their proportions. Another unique aspect of the invention is to provide ingredients with high concentration of proteins such as tissue and organs offish, poultry, animals and others. Offal ingredients are most preferred.
  • the second preferred method of producing the medium of the invention comprise providing at least one food/plant ingredient such as a vegetable, fruit, berry or herb as described above and one high protein ingredient such as an offal component, mushroom, sea product (fish, mussel, plankton for example), egg or nut. Proportion for plant with high protein ingredient and Hquid is ranging from 15-80% soHds to 20-85% Hquid.
  • the processing parameters may be opened up somewhat without compromising the completeness of the fermentation process and achieving high acidity at the end.
  • the temperature range in this case is about 10 to 58 degrees C and the time range is 3 to 20 days. It is still preferred to maintain higher temperature of about 32 to 47 degrees C and ferment the medium for at least 5 days so the acidity reaches a level above 300 T°.
  • composition of and preparation process for the medium of the invention are described in the foUowing steps:
  • [0047] Provide for sprouting of at least one grain such as rye, lentil, wheat or barley, and beans for 2-6 days at 20-30 degrees C in humid air. At the end of this period, grains can be optionally seeded with food-grade fungi such as AspergiUus niger and/or Aspergillus orizae to increase proteins concentration.
  • fungi such as AspergiUus niger and/or Aspergillus orizae to increase proteins concentration.
  • a biocompatible Hquid such as sterile milk or whey for 1 to 24 hours at 20-35 degrees C with at least one of selected non-pathogenic microorganisms such as bacteriayeasts.
  • the number of Uve bacteria at this point is in the general range of from about 10 7 to 10 9 per ml of Hquid, and pH is maintained close to neutral.
  • fermentation in water or juice can also be used.
  • non-pathogenic bacteria examples include, but not limited to, all strains of LactobacilH, Bifidobacteria, Streptococci, Pedicocci, Leuconostoc, Propionic and Acetic bacteria.
  • the yeast is Brewer's or Baker's yeast, which is added in active or non-active form (dried, autolyzed, hydrolyzed or extract).
  • These non- pathogenic bacteriayeasts can be alternately added without inoculation, immediately after the mixing of the various ingredients according to step 4. In this case however, fermentation wiU require more time.
  • Preferred strains of lactobacilH to be used in the medium of the invention include, but not limited to, lactobacillus acidophilus, lactobaciUus bifudus, lactobaciUus brevis, lactobacillus bulgaricus, lactobacillus delbrucki, lactobacillus casei, lactobacillus ceUobiosus, lactobacillus fermentum, lactobaciUus gasseri, lactobacillus germentum, lactobaciUus helveticus, lactobaciUus johnsonn, lactobacillus lactis, lactobacillus leichimami, lactobaciUus plantarum, lactobacUlus reuteri, lactobacUlus rhamnosus, lactobacUlus sake, lactobacUlus salivaroes, lactobacillus thermophilus and lactobacUlus xylosus.
  • Preferred strains of Bifidobacteria include Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium cereus, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium thermophilus.
  • Streptococci strains to be used include preferably Streptococcus lactis, Streptococcus cremoris, Streptococcus diacetylactis, Streptococcus thermophUus, and Streptococcus faecium.
  • Preferred yeast includes Saccharomyces boulardii, Saccharomyces cerevisiae, and Saccharomyces lactis.
  • Propionic bacteria strain is preferably propionibacterium shermanii.
  • Pedicocci strains that may be used in the present invention include Pediococcus cerevisia, Pediococcus acidilactici and Pediococcus pentosaceus.
  • Leuconostoc strains include Leuconostoc cremoris, Leuconostoc dextranicum, and Leuconostoc mesenteriodes.
  • [0057] 3. Provide other ingredients as specified below to include at least one type of dried or preferably fresh vegetables, fruits, berries, offal, and herbs, all thoroughly washed with water in addition to a product of beekeeping, mash, and proteolytic ferments. All products, including sprouted grains, should be homogenized/pulverized or mechanicaUy processed, for example through juice extractor. In case of dried products, their amount should be 3-5 times less by weight, they should be soaked in an appropriate volume of water for some time (for minutes or hours depending on type of product) to produce the same quantity of mass as when using fresh ingredients.
  • Vegetables preferably used are of leaf and root types e.g. various cabbages, beets, rutabaga, carrot, pumpkin, spinach, beet, watermelon, melon, peanut, artichoke, eggplant, pepper sweet, asparagus, and tomato.
  • Fruits to be preferably used are apples, pears, kiwi, plums, citrus, apricots, grapes/raisins, mango, guava, bananas, biwa, cornel, fig, cherry plum, quince, peach, pomegranate, avocado, pineapple, date, papaya.
  • Berries preferably include raspberry, bUberry, guelder rose, dog rose, ash berry (red and black), currant (red, black, and white), sea-buckthorn berries, gooseberry, schizandra, blackberry, cowberry, bird cherry, cranberry, sweet cherry, cherry, and strawberry.
  • Preferred herbs and their roots are ginseng, celery, parsley, diU, dandelion, nettle, ginseng, and spinach.
  • Preferred high protein products are offals including spleen, kidney, heart, Hver, brains, maw, and stomach as weU as mushrooms, sea products (fish, mussel, plankton for example), eggs or nuts.
  • Preferred products of beekeeping are propolis, honey, royal jeUy, and poUen of flower.
  • [0059] 4. Mix the preferred composition of the above ingredients as follows: 25 to 80% by weight of inoculated milk or whey, 1 to 30% by weight of vegetables, 1-20% by weight of fruits, 1-20% by weight of berries, 1-15% by weight of herbs, 1-30% by weight of high protein ingredients, 0.1-5% by weight of products of beekeeping, 1-10% by weight of sprouting grains and beans, 1-15% by weight of mash, 0.1-1.0% by weight of proteolytic ferments (pepsin or alike).
  • sugar 0.1-30% by weight, and thoroughly mix into the medium.
  • Preferred types of sugar include glucose, fructose, sucrose, mannose, maltose, galactose, raffinose, corn syrup, lactose or other mono-, di- or polysaccharides, which can be utilized by LactobacilH or Bifidobacteria. These sugars can be used both in combination and alone.
  • [0061] 6 Provide at least one of the following chemical compounds: potassium, sodium, magnesium, calcium, trace of cobalt, trace of manganese, and alcohol.
  • the chemical compounds should be dissolved in water and added to the mixture.
  • horns and hoofs can be used, but this might worsen the taste of the product.
  • the resulting products, sour milk hydrolyzed medium and sediment, can be stored at room temperature for several months. When refrigerated at 2-15 degree C, it can last for up to several years without deterioration. No preservatives need to be added.
  • the acidity of the final Hquid medium product is about 300 to 900 T°, preferably between 500 to 800 T°, which corresponds to lactate concentration of between about 4.5% and 8%, and pH ranges from 1.5 to 6.5, preferably from about 3 to 4.
  • the products of the suggested fermentation process are not toxic and have appHcation in medicine, food industry, biotechnology, veterinary, animal, poultry, and fish husbandry, athletic sport as a food supplement, and/or therapeutic drugs and can be used as a prophylactic agents against diseases.
  • the medium was observed to be non-toxic, even for challenging groups of patients such as the elderly, hospitalized and the immunocompromised, including ADDS patients, expecting mother and babies.
  • the most pronounced effects of the medium of the present invention include immunomodulation, improving physiologic function at the ceUular level, for various organs and the entire body.
  • the medium of the invention has a broad spectrum of antimicrobial activity with the ability to destroy and/or inhibit growth of many different species of pathogenic organisms.
  • Methods of administration of the medium of the invention depend on the specific condition. For general application, oral administration is useful.
  • Other appHcations include: 1) the external transcutaneous appHcation as a bandage soaked in the medium placed over the skin above effected organs or coating the body (rubbing it into the skin), mostly the trunk and particularly lymph nodes, 2) inhalation, especiaUy for breathing disorders, 3) administration rectaUy via a retention enema, 4) dripping into the nose and ears, 5) intravenous injections (after removal or microorganisms via known means such as through a filter) for reducing infections and/or for intravenous nutrition, 6) intraperitoneal injections for reducing infections, and 7) intravaginaUy via a soaked tampon.
  • a proper dosage of the medium and sediment of the present invention in humans depends upon the particular needs.
  • the appHcation of the medium of the invention should be the most aggressive and combine several possible routes of administration.
  • an ADDS patient should take the medium of the invention oraUy 2-3 times a day at any time in the amount of about 1 to 2 ml kg of body weight in addition to coating the body with the medium as much skin area as possible, especiaUy lymph nodes, 1 to 2 times a day, in the morning and at night.
  • skin bandages soaked with the medium should be placed over the skin above effected organs 1-4 times a week.
  • the hydrolyzed fermented medium of the invention is effective in treating a variety of infectious viral diseases including Hepatitis A, B, and C; myxoviruses and influenza; herpes of various types; virus of poHomyeHtis; adenoviruses; various types of encephaUtis; proteus, and foot-and-mouth disease.
  • the medium is effective in treating human immunodeficiency virus (HIV) and ADDS. It can be used for Ebola, smallpox, Congo-Crimean hemorrhagic fewer, and yellow fewer.
  • Bacteria caused infections can also be treated with the medium of the invention and include tuberculosis; leprosy; cholera; various forms of meningitis and Legionnaire's disease; syphilis; gonorrhea; Lyme disease; typhus; various Streptococcuses and Staphylococcuses; anthrax; botuHsm; diphtheria; gangrene; tetanus; tularemia; chamydiae; plague; mycoplasmas; pathogenic E-coH; etc.
  • the medium is also effective in treating septic shock, toxic shock, and multiple organ failure.
  • the medium of the invention is also effective against various fungi including Candida, Pneumocystis, and various other lung infections.
  • the product of the invention is effective for Protozoa including various types of Plasmodium of malaria; Leishmaniasis; various Trypanosomas; Cryptosporidium, Toxoplasmosis, and Isospora, as wells as against various parasites of cattle. It can be successfully used against helminth infections.
  • the medium is useful in treating cancer including advanced cancer such as bladder cancer, breast cancer, colon cancer, gastrointestinal cancers, head and neck cancers, kidney cancer, leukemia, lymphogranulomatosis, Hver cancer, lymphoma, lung cancer, prostate cancer, ovary cancer, skin cancers, thymus cancer, thyroid cancers, tongue cancer, vagina cancer and uterus cancer.
  • advanced cancer such as bladder cancer, breast cancer, colon cancer, gastrointestinal cancers, head and neck cancers, kidney cancer, leukemia, lymphogranulomatosis, Hver cancer, lymphoma, lung cancer, prostate cancer, ovary cancer, skin cancers, thymus cancer, thyroid cancers, tongue cancer, vagina cancer and uterus cancer.
  • the medium is found to be effective for cardiovascular diseases including various insults and strokes (including paralysis); myocardial infarction including the use as a prophylactic agent and after infarction for patient recovery; cerebral thrombosis; myocarditis and aneurysms; ischemia; arteriosclerosis; coronary artery disease; hypertension; rheumatism; various abnormalities of blood coagulation system.
  • cardiovascular diseases including various insults and strokes (including paralysis); myocardial infarction including the use as a prophylactic agent and after infarction for patient recovery; cerebral thrombosis; myocarditis and aneurysms; ischemia; arteriosclerosis; coronary artery disease; hypertension; rheumatism; various abnormalities of blood coagulation system.
  • kidney and liver diseases including dialysis; pyelonephritis, kidney colic; stones in kidney and Hver; hemolytic jaundice.
  • the medium can be used for a broad range of digestion diseases: for gastrointestinal diseases including dysbacteriosis, dyspepsia, irritable bowel syndrome, insomnia, etc; various forms of diarrhea including heHcobacter pylori, clostridium difficile, diarrhea induced by cholera, AIDS, rotavirus, antibiotic- associated, etc.; for inflammatory bowel diseases such as Crohn's disease, ulcerative coUtis, GI Ulcers, etc.
  • Use in transplantation of organs is another area of interest. Good results were observed when the medium was used after the transplantation of kidney and gut; donor organs were not rejected. In many cases, patients avoided the need for transplantation after treatment with the medium of the invention.
  • the medium found use in treating neurodegenerative diseases, including Alzheimer's Disease/Dementia; Parkinson disease; encephalopathy; and sclerosis.
  • This medium can be also used for autoimmune diseases (arthritis, polyarthritis, and rheumatoid arthritis), to reduce inflammation, and aUergies of various etiologies.
  • the medium is effective against excessive radiation, both ionizing (including lethal total body) and ultraviolet. It can be used for healing wounds and for bone fractures. It was very successfuUy used in surgical patients.
  • Further areas of medical use include diabetic conditions; to improve general physical and mental abUities and endurance; for hypoxia, decompression disease; for healing skin in burn patients; alcoholic and drug abuse; hematoma resorbtion; for sexual dysfunctions and sexual diseases (vaginitis, urethritis, bladder infection, etc.); for reHef of side effects of menopause; for treating endometriosis; psoriasis; bronchitis; aU types of pain including chronic pain; gingivitis and parodontosis; atrophy; dystrophy; omphaHtis, otitis, sinusitis, and rhinitis; and for reduction in cholesterol level.
  • the medium of the invention can be used both alone and in conjunction with pharmaceutical drugs as adjuvant therapy.
  • the administration of the medium reduces considerably the toxic side effects of conventional therapy.

Abstract

A method of producing a hydrolyzed fermented medium containing microorganisms such as bacteria or yeast and the products of their metabolism in high concentration, the method includes providing at least one solid plant product reduced to small pieces and mixed with sugar and a biocompatible liquid such as milk for fermentation at a temperature of between 35 and 58 degrees C until the acidity of the medium reaches the range of 300 to 900 in Terner degrees. In an alternative embodiment, the medium is prepared by mixing in predetermined amounts of sprouted grains, biocompatible liquid inoculated with at least one of a variety of non-pathogenic microorganisms, vegetables, fruits, berries, high protein products, herbs, sugar, and a chemical element such as potassium. The mixture is then fermented at a selected temperature for a specified length of time to reach high acidity and high concentration of products of bacterial metabolism. A liquid phase is separated from a solid sediment phase and can be used to treat a wide variety of diseases including HIV/AIDS, viral infections, cardiovascular diseases, Alzheimer's and others as well as for other applications.

Description

TITLE
COMPOSITION AND METHOD TO PRODUCE AND USE FERMENTED HYDROLYZED PRODUCTS OF MICROBIAL METABOLISM
Field of the Invention
[0001] The present invention relates to a hydrolyzed medium made by fermentation with non-pathogenic microorganisms and to the process of manufacturing and use thereof. More particularly it relates to the production of sour milk based hydrolysate, which includes the fermentation of various food ingredients and plants Using various non-pathogenic bacteria/yeast ingredients and some food-grade fungi in milk/whey or water, in its liquid form or solid dried form.
[0002] The medium produced by this method has physiologically beneficial effects and therapeutic activity against various diseases, including several life-threatening conditions. It can also be used in cosmetic industry for improving skin and food industry for production of dairy products, to accelerate cheese ripening and maturation, to improve the cultivation and long-term storage/preservation of viable Lactobacilli, acetic, propionic and bifidobacteria in their most active state.
[0003] In animal husbandry, the medium of the invention can be used as a feed supplement, for prevention and treatment of infection diseases, for growth promotion, to improve feed conversion, and to increase the yield of useful products, such as milk and eggs.
Background of the Invention
[0004] The art of fermentation, i.e. the transformation of organic compounds with the aid of enzymes produced by microorganisms, is well known. Microbial activity is fairly well understood in the food industry. Fermentation is used widely in the production of alcoholic beverages, dairy products and some Oriental fermented foods, especially in tropical climates. [0005] About one hundred years ago, Metchnikoff developed a theory that the ingestion of soured milk could improve colonic microflora through the reduction of the "autointoxication effect" of the colon. Today, this concept has been improved, and this field is now known as probiotics and prebiotics, defined as "a live microbial food supplement, that beneficially effects the host animal by improving its intestinal microbial balance" and "non- digestible food ingredients that benefit the host by selectively stimulating the growth or activity of one or a number of bacteria in the colon". A "symbiotic" is a combination of probiotics and prebiotics that "beneficially effects the host by improving the survival and implantation of live microbial dietary supplements in the gastrointestinal tract by selectively stimulating the growth of, and or by activating the metabolism of, one or a number of health promoting bacteria".
[0006] The bacterial genera most often used in the field of probiotics are lactic acid bacteria, particularly Lactobacillus sp. and Bifidobacterium sp., these bacteria being important members of the gastrointestinal microflora of man and animals. Other microorganisms used as probiotics in humans include Escherichia coli, Streptococcus sp., Enterococcus sp., Bacteroides sp., Bacillus sp., Propionibacterium sp. and various fungi.
[0007] The external and internal surfaces of a human body are covered with bacteria. These organisms are traditionally referred to as "normal (friendly) flora", or symbionts with commensals. These friendly bacteria are involved in dynamic bio-film communications on the skin, mouth, naso-pharyngeal, intestinal and urogenital tracts, where the appropriate microflora exists. The human body depends on this friendly microflora: it helps in food digesting, produces vital vitamins and protects against various pathogens. The mechanisms by which probiotic microorganisms provide benefits for the internal and external surfaces of the host are numerous: competing with pathogens for food, preventing the adhesion of pathogens, antimicrobial activity, colonization resistance, various immune effects, adjuvant effect, antimutagenic effects, antigenotoxic effects, influence on enzyme activity, enzyme delivery and many others.
[0008] It is accepted that probiotics are usually targeted for use in intestinal disorders. The effectiveness of probiotics has been demonstrated in the prevention and treatment of a diverse spectrum of gastrointestinal disorders, such as antibiotic-associated diarrhea, infectious bacterial and viral diarrhea, etc. Some evidence suggests a role for probiotics in reducing the risk of colon cancer and the regression of tumors. For example, US Patent No. 5,308,615 by DeLoach and US Patent No. 5,478,557 by Nisbet describe a probiotic used for control of salmonella. Also, probiotics have been used therapeutically to lower cholesterol, to reduce blood pressure, treat rheumatoid arthritis, prevent cancer, and prevent or reduce the effects of atopic dermatitis, Crohn's disease, constipation as well as candidiasis and certain genitourinary tract infections such as bacterial vaginosis, vaginitis, or urinary tract infections. The immunomodualting action of probiotics is helpful in reduction of allergic reactions, stimulation of phagocytosis by peripheral blood leukocytes and secretory IgA, modulation of cytokine gene expression, and many other immunological effects.
[0009] PCT patent No. WO 00/75284 by Olshenitsky et. al. describes a probiotic composition comprising a volatile fraction of a plant extract prepared by steam distillation and suspended microorganism such as E-coli. E-coli is not exactly non-pathogenic and may cause some harm to humans in certain conditions. No fermentation process of medium ingredients with bacteria is described in arriving at the end product. Rather, evaporation and condensation is used which limits the end properties of the product. For example, without E- coli the product looses its antagonistic activity. Even with E-coli present, the antagonistic activity is limited because some pathogens can still grow in the medium during incubation for 24 hours.
[0010] Probiotic preparations currently on the market appear in various forms: in dairy products, processed into a product such as chewing gum, pills, capsules, etc., suspended in milk, freeze-dried or air-dried. They are generally composed of large numbers of one or more bacterial species that are common constituents of normal intestinal flora. Fermented milk (yogurt) and cheese are the most common foods with probiotics. US Patent No. 6,228,358 by Toba describes an antioxidation product made from fermented milk. Zhang describes red rice fermentation products in the US Patent No. 6,046,022. Other forms of probiotic preparations are freeze-dried or air-dried and they are available in tablets and in capsules. US Patent No. 5,702,927 by Murofushi describes bacteria containing xanthan gum. In some cases, probiotics have been suspended in an appropriate milieu for better survival. For example, US Patent No. 5,908,622 by Barclay describes growing of microflora in fermentation medium containing certain sodium salts. US Patent No. 6,294,166 by Hsia describes a method of stabilization of specifically dried bacterial compositions mixed with specific nutrients, yeast and soy protein, for long periods of time. Some authors, for example, US Patent Nos. 6,203,797 by Perry; 6,080,401 by Reddy; and 5,171,575 by Shibata, used various food/herb compositions with probiotics, without fermentation, to enhance medicinal effects.
[0011] Fermented cultures containing microorganisms can be used in other industries such as in cosmetics and pharmaceutical industry. US Patent No. 6,270,811 by Fregonese describes a composition containing a microbial culture for skin regenerating and removing scars and wrinkles.
[0012] Despite their health promoting effects, probiotics have only demonstrated short-term effects. In the study of the health effects of probiotics, the incidence and/or duration of acute, short term diseases, such as diarrhea, are frequently measured. The effects of probiotic bacteria on the incidence of diseases with a protracted etiology, such as cancer or heart disease, have generally not been measured. Moreover, the effects of probiotics in life- threatening diseases, such as cancer for example, are doubtful. For probiotics to have their therapeutic effect they should be used in high doses daily and the duration of their use should be sufficiently long.
[0013] Importantly, attention has been focused on the microorganisms per se, not their products of metabolism. Lactic acid fermentation is mainly considered for dairy products. Only in some oriental foods such as cassava, mixtures of grains and legumes, have lactic acid fermentation been used for the preparation of a variety of foods made from raw materials of plant and animal origin. Processed food tends to loose a substantial part of its useful components, ferments for example, as compared to raw materials.
[0014] US Patent No. 5,292,511 by Kim describes the lactic acid fermentation process being used for aloe preservation, and the end product used as a health-food supplement. The product and process described in the patent is limited in time (up to 96 hours) and temperature of fermentation (20-35 degrees C). At 40 degrees C the product is reported to start to decompose. The inventors of the present invention believe that the fermentation process is not complete from the point of view of the instant invention. [0015] US Patent No. 4,298,620 by Hagiwara proposes a fermentation process for obtaining a fermented tear grass product combining a water extract of tear grass with a Lactobacillus strain, and foods and feeds comprising that product. This patent is incorporated herein in its entirety. Importantly, one critical step in the process as described in this patent is heating of the tear grass before fermenting it. In our opinion, this step effectively damages all useful ferments contained in the grass and significantly reduces its effectiveness. Also, since the number of bacteria is not reduced at the end of cultivation, the acidity of the end product (as measured by concentration of lactate) is low at about 0.7 to 3%. Another limitation is the typical addition of sugar at the end of cultivation. Finally, a heat sterilization process at 80 degree C for 40 minutes effectively destroys all live microorganisms and active ingredients, ferments for example.
[0016] Other fermentation patents of interest include US Patent Nos. 5,219,597 by Mok; 5,700,684 by Ehret; 6,156,320 by Izvekova; 5,556,785 by Kishida; 5,747,020 by Rutherford; 4,407,828 by Raccach; 3,963,835 by Gryczka; 4,018,650 by Busta; 4,528,199 by Moon; 4,579,740 by Matrozza; 4,897,350 by El-Megeed; 4,749,652 by Robinson; 4,816,267 by Oka; 4,855,147 by Yokota; 4,579,739 by Derbyshire; 4,664,919 by Yan; 4,770,882 by Ingouf; and 3,944,676 by Fridman. They depict mostly various fermentation processes that are somewhat similar to the subject of the invention but in most cases these processes are short-term or carried out at low temperatures in solid phase and therefore incomplete from the point of view of the present invention.
[0017] One probable reason for limited effectiveness of probiotics in general is because of poor binding of the active microorganisms to the internal linings or external surface of the human body. Bacteria, especially in the state of freeze-dried suspension, have only limited time to develop a bond with the host. It takes several hours for the bacteria to become active after being consumed. Therefore, the bacteria are frequently expelled by natural processes such as digestion without allowing it to bond to the intestines and to produce enzymes, vitamins, amino acids, organic acids and other products of their metabolism. It is these metabolic products that represent the ultimate goal of the application of microorganisms. Live microorganisms might have a better chance to remain on the surface and tissue lining and attach thereto. [0018] The need therefore exists for a medium containing live microorganisms as well as their metabolic products in high concentrations. Its application for humans is believed to be more effective and provide long-term benefits than the presently known suspensions of such microorganisms mostly in inactive state, even consumed in a high concentration.
Summary of the Invention
[0019] It is an object of the present invention to provide a composition for a biologically benign medium containing non-pathogenic microorgamsms and their metabolic products, such as enzymes with high proteolytic activity, vitamins, amino acids, low molecular weight proteins, organic acids, microelements and others.
[0020] It is another object of the invention to provide a fermented medium allowing the microorganisms to remain alive in active state so that better conditions are created for attachment thereof to the appropriate tissue of the host.
[0021] A further object of the present invention is to provide a medium of high acidity, at least above 3% of lactate concentration (>300 T°), to promote higher vitality of those microorganisms that survive in the process of natural selection in a harsh for them acidic environment. It is noted here that lactate also plays a role of a preservative for the medium of the invention.
[0022] It is another object of the invention to provide such medium based on raw natural fish, animal, and plant products not subjected to heavy food processing or application of heat to retain and preserve original ferments and other useful ingredients.
[0023] It is another object of the present invention to provide a method for producing such medium. A further object is to provide a process of deep fermentation of the medium with appropriate microorganisms to cause production of metabolic products useful for human beings. [0024] It is a further object of the present invention to provide methods of use of the medium of the invention in medicine, food, cosmetics, and other industries.
[0025] It is a further yet objective to provide a medium capable of producing long-term therapeutic effects on a human being or an animal.
[0026] In accordance with the present invention, a new symbiotic multi-component fermented hydrolyzed medium is provided with a broad spectrum of antibacterial, antiviral and anti-fungal properties, and antagonistic activity against Protozoa. The medium is produced with non-pathogenic microorgamsms, and has a high concentration of aromatic organic acids such as lactate, acetate, propionic, and other organic acids as metabolic end products of the fermentation process. The medium of the invention contains live non- pathogenic microorganisms in low concentrations and the products of their intensive metabolism, thereby keeping microorganisms in their most active alive condition. It is also believed that the bacteria that remain alive have more vitality, due to the natural selection of those that can survive in the environment of high acidity.
[0027] Non-pathogenic microorganisms genera used are Lactobacilli, Bifidobacteria, Acetic and Propionic bacteria, yeasts and food-grade fungi.
[0028] According to the invention, the fermentation process for obtaining sour-milk hydrolyzed medium is as follows. Initial ingredients include certain raw or dried vegetables, fruits, berries, offal, fish, eggs, plants, herbs, mash, sprouted grains and beans, aquatic plants, products of beekeeping, sea products, mushrooms, proteolytic ferments, chemicals and various types of sugar in the appropriate amounts. The ingredients are mixed in predetermined proportions and fermented with non-pathogenic bacteria or yeasts and certain food-grade fungi in milk or whey. Fermentation can also take place in water or another appropriate biocompatible liquid. The fermentation process takes 3-14 days (preferably 5-10 days) at 10-58 degrees C (preferably 32-47 degrees C) and can be carried out both aerobically and anaerobically. Typically, sour milk hydrolyzed medium includes about 105 to 106 live bacteria/yeasts cells per 1.0 g of product, and comprise 1 to 30 percent by weight of protein, all essential amino acids (resulting from the partial proteolysis of proteins during culturing), organic acids, microelements and vitamins. The acidity of the final product is about 300 to 900 T°, preferably between 500 to 800 T°, which corresponds to lactate concentration of between about 4.5% and 8%, and pH ranges from 1.5 to 6.5, preferably from about 3 to 4. There is no heat processing or pasteurization used in preparation of the medium.
[0029] The medium of the invention is not toxic and quite safe, and can be successfully utilized in high-risk patients, such as the elderly, hospitalized and the immunocompromised, including AIDS patients. No side effects were observed in babies or pregnant women in our studies.
[0030] The efficacy of the medium of the invention is comparable to modern pharmacological drugs (antibiotics, and antiviral and anti-fungal compounds). Moreover, this medium was effective against life-threatening diseases, such as cancer, tuberculosis, HΓV/AΓDS, and others, where traditional pharmacological drugs failed. No drug interaction was observed between pharmacological drugs and the medium of the present invention. On the contrary, the medium reduced considerably the side effects caused by toxic pharmacological drugs.
[0031] The medium can be used in food industry during the production of dairy products and cheese to accelerate cheese ripening and maturation, and as a method to cultivate and store for a long time in their most active condition Lactobacilli, acetic, propionic and bifidobacteria.
[0032] This medium can be used on farms as a feed supplement in animal husbandry for the prevention and treatment of infection diseases and to promote growth.
[0033] The medium of the invention can be used in cosmetic to improve skin condition (increasing skin elasticity and regeneration), to reduce and remove hems, scars and wrinkles, for healing burnt skin and as cream for sunburn.
[0034] The medium was found to possess a broad spectrum of therapeutic potential (the application was not limited to only GI tract) including reduction of DNA damage of the host cells. Boosting the immune system, immunomodulation, normalization of the number and function of blood cells, especially lymphocytes, are the most pronounced effects of this medium. These effects appear to be mainly caused by the end products of bacteria's metabolism.
[0035] Methods of administration of medium of the invention, in addition to accepted oral and intravaginal administration, include: 1) the external application to the skin as a bandage to the effected organs or coating the body (rubbing it into the skin), mostly the trunk and lymph nodes, 2) inhalation, 3) administration rectally via a retention enema, 4) dripping into the nose and ears, 5) intravenous injections for reducing infections and/or for intravenous nutrition, and 6) intraperitoneal injections for reducing infections.
[0036] The above and other objects, aspects, features and advantages of the invention will be more readily apparent from the description of the preferred embodiments thereof taken in conjunction with the appended claims.
Detailed Description of the Preferred Embodiments
[0037] The first most important and unique aspect of the present invention is providing temperature and time conditions for the process of fermentation which ensure that at the end the fermentation is deep and complete. We found that generally at a point of about three days into the process of fermentation, most pathogens are destroyed/replaced. The medium of the present invention has to be fermented for at least 3 and preferably 5 to 14 days at a temperature of at least 10 and preferably 35 to 58 degrees C to make sure that no pathogens are present. Another objective for this long time and higher temperature (as opposed to what is described in the prior art) is to make sure that microorganisms have adequate conditions to release products of their metabolism into the medium. By the end of the process, the medium has high acidity (generally, from 300 to 900 T°), low pH (from 1.5 to 6.5), high concentration of the metabolic products and relatively low concentration of microorganisms (from 105 to 106 cells/ml) as opposed to the preparations described by others.
[0038] In the most basic form, the medium of the invention can be prepared following these steps: [0039] 1. Provide a food product of plant nature, wash it and cut into small pieces (dimension of pieces can vary from about 1/2 millimeter to 4 centimeters). Juice extractor may be used for such purpose. The smaller the pieces are, the better hydrolysis will be achieved. A wide variety of food or plant products may be used, for example most fruits, vegetables, berries and herbs.
[0040] 2. Provide a biocompatible Hquid such as water, juice, etc. Most preferably, whey or milk or their combination may be used. Lemon, orange, or grape juice is another preferred biocompatible liquid.
[0041] 3. Mix the food ingredient with the Hquid ingredient in proportions of about 10-90% liquid to about 70-5% food by weight.
[0042] 4. Add sugar to this mixture at about 0.1-30% by weight. Mix thoroughly and place in a thermostat for about 5-14 days at 32-58 degrees C.
[0043] Ambient microorganisms cause fermentation to proceed. For whey and milk, it is a naturally present Lactobacillus. Optionally and to better control fermentation, appropriate strain of microorganism can be specificaUy added, Lactobacillus bulgaricus for example.
[0044] The fermentation endpoint is determined by measuring the acidity in Terner degree. A satisfactory acidity for the medium is between 300 and 900 T°, and pH ranges between 1.5 to 6.5.
[0045] The strength and quality of the fermented medium of the invention depends on the number and nature of various ingredients and their proportions. Another unique aspect of the invention is to provide ingredients with high concentration of proteins such as tissue and organs offish, poultry, animals and others. Offal ingredients are most preferred. As such, the second preferred method of producing the medium of the invention comprise providing at least one food/plant ingredient such as a vegetable, fruit, berry or herb as described above and one high protein ingredient such as an offal component, mushroom, sea product (fish, mussel, plankton for example), egg or nut. Proportion for plant with high protein ingredient and Hquid is ranging from 15-80% soHds to 20-85% Hquid. In comparison to the first embodiment, the processing parameters may be opened up somewhat without compromising the completeness of the fermentation process and achieving high acidity at the end. The temperature range in this case is about 10 to 58 degrees C and the time range is 3 to 20 days. It is still preferred to maintain higher temperature of about 32 to 47 degrees C and ferment the medium for at least 5 days so the acidity reaches a level above 300 T°.
[0046] According to the third preferred embodiment and to achieve maximum strength, the composition of and preparation process for the medium of the invention are described in the foUowing steps:
[0047] 1. Provide for sprouting of at least one grain such as rye, lentil, wheat or barley, and beans for 2-6 days at 20-30 degrees C in humid air. At the end of this period, grains can be optionally seeded with food-grade fungi such as AspergiUus niger and/or Aspergillus orizae to increase proteins concentration.
[0048] 2. Inoculate a biocompatible Hquid such as sterile milk or whey for 1 to 24 hours at 20-35 degrees C with at least one of selected non-pathogenic microorganisms such as bacteriayeasts. The number of Uve bacteria at this point is in the general range of from about 107 to 109 per ml of Hquid, and pH is maintained close to neutral. OptionaUy, fermentation in water or juice can also be used.
[0049] Examples of non-pathogenic bacteria that can be used for the medium of the invention include, but not limited to, all strains of LactobacilH, Bifidobacteria, Streptococci, Pedicocci, Leuconostoc, Propionic and Acetic bacteria. The yeast is Brewer's or Baker's yeast, which is added in active or non-active form (dried, autolyzed, hydrolyzed or extract). These non- pathogenic bacteriayeasts can be alternately added without inoculation, immediately after the mixing of the various ingredients according to step 4. In this case however, fermentation wiU require more time.
[0050] Preferred strains of lactobacilH to be used in the medium of the invention include, but not limited to, lactobacillus acidophilus, lactobaciUus bifudus, lactobaciUus brevis, lactobacillus bulgaricus, lactobacillus delbrucki, lactobacillus casei, lactobacillus ceUobiosus, lactobacillus fermentum, lactobaciUus gasseri, lactobacillus germentum, lactobaciUus helveticus, lactobaciUus johnsonn, lactobacillus lactis, lactobacillus leichimami, lactobaciUus plantarum, lactobacUlus reuteri, lactobacUlus rhamnosus, lactobacUlus sake, lactobacUlus salivaroes, lactobacillus thermophilus and lactobacUlus xylosus.
[0051] Preferred strains of Bifidobacteria include Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium cereus, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium thermophilus.
[0052] Streptococci strains to be used include preferably Streptococcus lactis, Streptococcus cremoris, Streptococcus diacetylactis, Streptococcus thermophUus, and Streptococcus faecium.
[0053] Preferred yeast includes Saccharomyces boulardii, Saccharomyces cerevisiae, and Saccharomyces lactis.
[0054] Propionic bacteria strain is preferably propionibacterium shermanii.
[0055] Pedicocci strains that may be used in the present invention include Pediococcus cerevisia, Pediococcus acidilactici and Pediococcus pentosaceus.
[0056] Leuconostoc strains include Leuconostoc cremoris, Leuconostoc dextranicum, and Leuconostoc mesenteriodes.
[0057] 3. Provide other ingredients as specified below to include at least one type of dried or preferably fresh vegetables, fruits, berries, offal, and herbs, all thoroughly washed with water in addition to a product of beekeeping, mash, and proteolytic ferments. All products, including sprouted grains, should be homogenized/pulverized or mechanicaUy processed, for example through juice extractor. In case of dried products, their amount should be 3-5 times less by weight, they should be soaked in an appropriate volume of water for some time (for minutes or hours depending on type of product) to produce the same quantity of mass as when using fresh ingredients.
[0058] Vegetables preferably used are of leaf and root types e.g. various cabbages, beets, rutabaga, carrot, pumpkin, spinach, beet, watermelon, melon, peanut, artichoke, eggplant, pepper sweet, asparagus, and tomato. Fruits to be preferably used are apples, pears, kiwi, plums, citrus, apricots, grapes/raisins, mango, guava, bananas, biwa, cornel, fig, cherry plum, quince, peach, pomegranate, avocado, pineapple, date, papaya. Berries preferably include raspberry, bUberry, guelder rose, dog rose, ash berry (red and black), currant (red, black, and white), sea-buckthorn berries, gooseberry, schizandra, blackberry, cowberry, bird cherry, cranberry, sweet cherry, cherry, and strawberry. Preferred herbs and their roots are ginseng, celery, parsley, diU, dandelion, nettle, ginseng, and spinach. Preferred high protein products are offals including spleen, kidney, heart, Hver, brains, maw, and stomach as weU as mushrooms, sea products (fish, mussel, plankton for example), eggs or nuts. Preferred products of beekeeping are propolis, honey, royal jeUy, and poUen of flower.
[0059] 4. Mix the preferred composition of the above ingredients as follows: 25 to 80% by weight of inoculated milk or whey, 1 to 30% by weight of vegetables, 1-20% by weight of fruits, 1-20% by weight of berries, 1-15% by weight of herbs, 1-30% by weight of high protein ingredients, 0.1-5% by weight of products of beekeeping, 1-10% by weight of sprouting grains and beans, 1-15% by weight of mash, 0.1-1.0% by weight of proteolytic ferments (pepsin or alike).
[0060] 5. Provide specified amount of sugar, 0.1-30% by weight, and thoroughly mix into the medium. Preferred types of sugar include glucose, fructose, sucrose, mannose, maltose, galactose, raffinose, corn syrup, lactose or other mono-, di- or polysaccharides, which can be utilized by LactobacilH or Bifidobacteria. These sugars can be used both in combination and alone.
[0061] 6. Provide at least one of the following chemical compounds: potassium, sodium, magnesium, calcium, trace of cobalt, trace of manganese, and alcohol. The chemical compounds should be dissolved in water and added to the mixture. Optionally, horns and hoofs can be used, but this might worsen the taste of the product.
[0062] 7. Ferment aU of the above ingredients aerobicaUy or anaerobically for 3-20 days at 10-58 degrees C. It is preferred to ferment the mixture for 5-10 days at 32-47 degrees C. [0063] 8. After fermentation, separate the Hquid (for example by filtering of with a centrifuge), which constitutes the desired sour milk hydrolyzed medium of the invention. The number of live bacteria in the liquid medium at the end of fermentation is about 105 to 106 per one gram of Hquid. The removed sediment contains aU the useful ingredients as well and the same bacteria and can be used as feed supplement for human consumption and in animal husbandry. The sediment can be alternatively lyophilized at room temperature and stored for later consumption.
[0064] The resulting products, sour milk hydrolyzed medium and sediment, can be stored at room temperature for several months. When refrigerated at 2-15 degree C, it can last for up to several years without deterioration. No preservatives need to be added.
[0065] The acidity of the final Hquid medium product is about 300 to 900 T°, preferably between 500 to 800 T°, which corresponds to lactate concentration of between about 4.5% and 8%, and pH ranges from 1.5 to 6.5, preferably from about 3 to 4.
[0066] The products of the suggested fermentation process are not toxic and have appHcation in medicine, food industry, biotechnology, veterinary, animal, poultry, and fish husbandry, athletic sport as a food supplement, and/or therapeutic drugs and can be used as a prophylactic agents against diseases. The medium was observed to be non-toxic, even for challenging groups of patients such as the elderly, hospitalized and the immunocompromised, including ADDS patients, expecting mother and babies. The most pronounced effects of the medium of the present invention include immunomodulation, improving physiologic function at the ceUular level, for various organs and the entire body. The medium of the invention has a broad spectrum of antimicrobial activity with the ability to destroy and/or inhibit growth of many different species of pathogenic organisms.
[0067] Methods of administration of the medium of the invention depend on the specific condition. For general application, oral administration is useful. Other appHcations include: 1) the external transcutaneous appHcation as a bandage soaked in the medium placed over the skin above effected organs or coating the body (rubbing it into the skin), mostly the trunk and particularly lymph nodes, 2) inhalation, especiaUy for breathing disorders, 3) administration rectaUy via a retention enema, 4) dripping into the nose and ears, 5) intravenous injections (after removal or microorganisms via known means such as through a filter) for reducing infections and/or for intravenous nutrition, 6) intraperitoneal injections for reducing infections, and 7) intravaginaUy via a soaked tampon.
[0068] A proper dosage of the medium and sediment of the present invention in humans depends upon the particular needs. In case of a life threatening condition, the appHcation of the medium of the invention should be the most aggressive and combine several possible routes of administration. As an example, an ADDS patient should take the medium of the invention oraUy 2-3 times a day at any time in the amount of about 1 to 2 ml kg of body weight in addition to coating the body with the medium as much skin area as possible, especiaUy lymph nodes, 1 to 2 times a day, in the morning and at night. In case of liver, kidney, pancreas, etc. intoxication caused by HAART, skin bandages soaked with the medium should be placed over the skin above effected organs 1-4 times a week. In case of lung problems, additional inhalation on a daUy basis is needed as weU. Our evaluation showed that aU lung infections in AIDS patients disappeared within 1-3 weeks. Additionally, rectal administration, typically with oil, should be used 3-5 times a week. Women should use intravaginal tampons at least 2-4 times a week for up to 2 hours at a time. Our studies demonstrated that as a result of such intensive therapy, opportunistic infections resolved mostly within 2-8 weeks, CD4 increased by 20-30 cells/month, accompanied with increasing CD8 and ratio CD4/CD8. After 1-4 months of such therapy, it can be interrupted for 1-3 weeks or the doses and/or number of methods of administration can be reduced. For a less serious condition, oral administration is generally enough.
[0069] The hydrolyzed fermented medium of the invention is effective in treating a variety of infectious viral diseases including Hepatitis A, B, and C; myxoviruses and influenza; herpes of various types; virus of poHomyeHtis; adenoviruses; various types of encephaUtis; proteus, and foot-and-mouth disease. The medium is effective in treating human immunodeficiency virus (HIV) and ADDS. It can be used for Ebola, smallpox, Congo-Crimean hemorrhagic fewer, and yellow fewer.
[0070] Bacteria caused infections can also be treated with the medium of the invention and include tuberculosis; leprosy; cholera; various forms of meningitis and Legionnaire's disease; syphilis; gonorrhea; Lyme disease; typhus; various Streptococcuses and Staphylococcuses; anthrax; botuHsm; diphtheria; gangrene; tetanus; tularemia; chamydiae; plague; mycoplasmas; pathogenic E-coH; etc. The medium is also effective in treating septic shock, toxic shock, and multiple organ failure.
[0071] The medium of the invention is also effective against various fungi including Candida, Pneumocystis, and various other lung infections.
[0072] The product of the invention is effective for Protozoa including various types of Plasmodium of malaria; Leishmaniasis; various Trypanosomas; Cryptosporidium, Toxoplasmosis, and Isospora, as wells as against various parasites of cattle. It can be successfully used against helminth infections.
[0073] The medium is useful in treating cancer including advanced cancer such as bladder cancer, breast cancer, colon cancer, gastrointestinal cancers, head and neck cancers, kidney cancer, leukemia, lymphogranulomatosis, Hver cancer, lymphoma, lung cancer, prostate cancer, ovary cancer, skin cancers, thymus cancer, thyroid cancers, tongue cancer, vagina cancer and uterus cancer.
[0074] The medium is found to be effective for cardiovascular diseases including various insults and strokes (including paralysis); myocardial infarction including the use as a prophylactic agent and after infarction for patient recovery; cerebral thrombosis; myocarditis and aneurysms; ischemia; arteriosclerosis; coronary artery disease; hypertension; rheumatism; various abnormalities of blood coagulation system.
[0075] Another area of use in medicine is for kidney and liver diseases including dialysis; pyelonephritis, kidney colic; stones in kidney and Hver; hemolytic jaundice.
[0076] Of course, the medium can be used for a broad range of digestion diseases: for gastrointestinal diseases including dysbacteriosis, dyspepsia, irritable bowel syndrome, insomnia, etc; various forms of diarrhea including heHcobacter pylori, clostridium difficile, diarrhea induced by cholera, AIDS, rotavirus, antibiotic- associated, etc.; for inflammatory bowel diseases such as Crohn's disease, ulcerative coUtis, GI Ulcers, etc. [0077] Use in transplantation of organs is another area of interest. Good results were observed when the medium was used after the transplantation of kidney and gut; donor organs were not rejected. In many cases, patients avoided the need for transplantation after treatment with the medium of the invention.
[0078] The medium found use in treating neurodegenerative diseases, including Alzheimer's Disease/Dementia; Parkinson disease; encephalopathy; and sclerosis.
[0079] This medium can be also used for autoimmune diseases (arthritis, polyarthritis, and rheumatoid arthritis), to reduce inflammation, and aUergies of various etiologies.
[0080] The medium is effective against excessive radiation, both ionizing (including lethal total body) and ultraviolet. It can be used for healing wounds and for bone fractures. It was very successfuUy used in surgical patients.
[0081] Further areas of medical use include diabetic conditions; to improve general physical and mental abUities and endurance; for hypoxia, decompression disease; for healing skin in burn patients; alcoholic and drug abuse; hematoma resorbtion; for sexual dysfunctions and sexual diseases (vaginitis, urethritis, bladder infection, etc.); for reHef of side effects of menopause; for treating endometriosis; psoriasis; bronchitis; aU types of pain including chronic pain; gingivitis and parodontosis; atrophy; dystrophy; omphaHtis, otitis, sinusitis, and rhinitis; and for reduction in cholesterol level.
[0082] The medium of the invention can be used both alone and in conjunction with pharmaceutical drugs as adjuvant therapy. The administration of the medium reduces considerably the toxic side effects of conventional therapy.
[0083] Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and appUcations of the present invention. It is therefore to be understood that numerous modifications may be made to the iUustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.

Claims

What is claimed is:
1. A method for producing a fermented hydrolyzed medium containing non-pathogenic microorganisms and products of their metaboHsm by providing a soHd food ingredient reduced to smaU pieces and a biocompatible Hquid ingredient, the improvement comprising the steps of:
a) mixing said solid food ingredient with said liquid ingredient in proportions of about 10-90% liquid to about 70-5% soHd food by weight;
b ) adding sugar by mixing it into the mixture at about 0.1 -30% by weight; and
c) fermenting the mixture at 35-58 degrees C until acidity reaches a range between 300 and 900 T°; whereby obtaining high acidity medium with high concentration of microorganisms and products of their metabolism.
2. The method of claim 1 , wherein said soHd food ingredient a plant.
3. The method as in claim 2, wherein said plant is selected from the group consisting of vegetables, herbs, grains, and fruits.
4. The method as in claim 1, wherein said biocompatible Hquid ingredient is selected from the group consisting of water, juice, milk, whey, and combination of whey and milk.
5. A method for producing a fermented hydrolyzed medium containing non-pathogenic microorganisms and products of their metaboHsm by providing a soUd plant ingredient reduced to small pieces, a solid high protein ingredient reduced to small pieces, and a biocompatible Hquid ingredient, the improvement comprising the steps of:
a) mixing said plant, high protein, and liquid ingredients with sugar in proportions by weight of about 15-80% soHds to 20-85% Hquid; and b) fermenting the mixture for about 3-14 days at about 10-58 degrees C;
whereby obtaining said medium with high acidity of over 300 T°.
6. The method as in claim 5, wherein said plant ingredient is selected from the group consisting of vegetables, herbs, berries, grains, and fruits.
7. The method as in claim 5, wherein said biocompatible liquid ingredient is selected from the group consisting of water, juice, milk, whey, and combination of whey and milk.
8. The method as in claim 5, wherein said high protein ingredient is an offal product.
9. The method as in claim 5, wherein said high protein ingredient is a sea product.
10. The method as in claim 5, wherein the step of fermenting is conducted at a temperature of about 35-47 degrees C for about 5-14 days.
11. A method for producing a fermented hydrolyzed medium containing non-pathogenic microorganisms and products of their metabolism by providing a sprouting grain ingredient reduced to small pieces and a biocompatible Hquid ingredient, the improvement comprising the steps of:
a) inoculating said Hquid ingredient with at least one non-pathogenic microorganism;
b) providing a vegetable ingredient, a fruit ingredient, a berry ingredient, a high protein ingredient, an herb ingredient, a beekeeping ingredient, a mash ingredient, and a proteolytic ferment ingredient, all said ingredients reduced to smaU pieces;
c) mixing the ingredients by weight as follows: about 25-80% of said Hquid ingredient, about 1-30% of said vegetable ingredient, about 1-20% of said fruit ingredient, about 1-20% of said berry ingredient, about 1-15% of said herb ingredient, about 1-30% of said high protein ingredient, about 0.1-5% of said beekeeping ingredient, about 1-10% of said sprouting grain ingredient, about 1-15% of said mash ingredient, and about 0.1-1.0% of said proteolytic ferment ingredient; d) adding about 0.1-30% by weight of a sugar ingredient;
e) dissolving in water and adding to the mixture of a chemical ingredient selected from the group consisting of potassium, sodium, magnesium, trace of cobalt, trace of manganese, calcium, and alcohol;
f) fermenting all the above ingredients in the mixture for about 3-14 days at about 10-58 degrees C; and
g) separating a Hquid portion of the mixture constituting said fermented hydrolyzed medium.
12. The method as in claim 11, wherein said sprouting grain ingredient is selected from the group consisting of rye, lentU, wheat, barley, and beans.
13. The method as in claim 11, wherein step a) further including a step of sprouting said grain ingredient for about 2-6 days at about 20-30 degrees C in humid air environment.
14. The method as in claim 11, wherein said step a) further including seeding said sprouting grain ingredient with food-grade fungi.
15. The method as in claim 11, wherein said biocompatible Hquid ingredient is a sterile milk or whey.
16. The method as in claim 11, wherein said non-pathogenic microorganism is a non- pathogenic bacteria or yeast.
17. The method as in claim 16, wherein said non-pathogenic bacteria is selected from the group consisting of LactobacilH, Bifidobacteria, Streptococci, Pedicocci, Leuconostoc, Propionic and Acetic bacteria.
18. The method as in claim 17, wherein said LactobacilH bacteria is selected from the group consisting of lactobacillus acidopbilus, lactobacillus bifudus, lactobaciUus brevis, lactobacUlus bulgaricus, lactobaciUus delbrucki, lactobacillus casei, lactobacUlus ceUobiosus, lactobacUlus fermentum, lactobacUlus gasseri, lactobacUlus germentum, lactobaciUus helveticus, lactobaciUus johnsomi, lactobaciUus lactis, lactobacUlus leichimanii, lactobacillus plantarum, lactobacUlus reuteri, lactobacillus rhamnosus, lactobacillus sake, lactobacUlus saHvaroes, lactobaciUus thermophUus and lactobacUlus xylosus.
19. The method as in claim 17, wherein said Bifidobacteria is selected from the group consisting of Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium cereus, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium thermophilus.
20. The method as in claim 17, wherein said Streptococci bacteria is selected from the group consisting of Streptococcus lactis, Streptococcus cremoris, Streptococcus diacetylactis, Streptococcus thermophilus, and Streptococcus faecium.
21. The method as in claim 11, wherein said vegetable ingredient is a leaf or root vegetable selected from the group consisting of cabbage, beet, rutabaga, carrot, pumpkin, spinach beet, watermelon, melon, peanut, artichoke, eggplant, pepper sweet, asparagus, and tomato.
22. The method as in claim 11, wherein said fruit ingredient is selected from the group consisting of apple, pear, kiwi, plum, citrus, apricot, grape, raisin, mango, guava, biwa, cornel, fig, cherry plum, quince, peach, pomegranate, avocado, pineapple, date, papaya, and banana.
23. The method as in claim 11, wherein said berry ingredient is selected from the group consisting of raspberry, bilberry, guelder rose, dog rose, red ash berry, black ash berry, red currant, black currant, white currant, sea-buckthorn berry, gooseberry, schizandra, blackberry, cowberry, bird cherry, cranberry, sweet cherry, cherry, and strawberry.
24. The method as in claim 11, wherein said herb mgredient is selected from the group consisting of ginseng, celery, parsley, dill, dandelion, nettle, and spinach.
25. The method as in claim 11, wherein said offal ingredient is selected from the group consisting of spleen, kidney, heart, Hver, brains, maw, and stomach.
26. The method as in claim 11, wherein said beekeeping ingredient is selected from the group consisting of propolis, honey, royal jeUy, and poUen of flower.
27. The method as in claim 11, wherein said proteolytic ferment ingredient is pepsin.
28. The method as in claim 11, wherein said sugar ingredient is selected from the group consisting of glucose, fructose, sucrose, mannose, maltose, galactose, raffinose, corn syrup, and lactose.
29. The method as in claim 11, wherein step g) includes adding of horns and hoofs.
30. The method as in claim 11, wherein step h) includes fermentation for about 5-14 days at a temperature of about 32-47 degrees C.
31. The method as in claim 11, wherein the last step of separating the liquid portion of mixture includes collecting a solid sediment portion of mixture for further human consumption or use in animal husbandry.
PCT/US2003/018831 2002-06-21 2003-06-13 Composition and method to produce and use fermented hydrolyzed products of metabolism WO2004000038A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003236536A AU2003236536A1 (en) 2002-06-21 2003-06-13 Composition and method to produce and use fermented hydrolyzed products of metabolism
CA2484639A CA2484639C (en) 2002-06-21 2003-06-13 Composition and method to produce and use fermented hydrolyzed products of miocrobial metabolism

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/178,447 US6953574B2 (en) 2002-06-21 2002-06-21 Method for producing a fermented hydrolyzed medium containing microorganisms
US10/178,447 2002-06-21

Publications (1)

Publication Number Publication Date
WO2004000038A1 true WO2004000038A1 (en) 2003-12-31

Family

ID=29734690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018831 WO2004000038A1 (en) 2002-06-21 2003-06-13 Composition and method to produce and use fermented hydrolyzed products of metabolism

Country Status (4)

Country Link
US (2) US6953574B2 (en)
AU (1) AU2003236536A1 (en)
CA (1) CA2484639C (en)
WO (1) WO2004000038A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210505A1 (en) * 2009-01-27 2010-07-28 Nestec S.A. Composition comprising caftaric acid and/or derivatives thereof
CN105192828A (en) * 2015-11-02 2015-12-30 广西金臣科技有限公司 Mango enzyme nutrient solution and preparation method thereof
CN113142451A (en) * 2021-05-12 2021-07-23 河北一然生物科技有限公司 Chinese herbal medicine fermentation inoculant and preparation method of fermented Chinese herbal medicine beverage

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216650D0 (en) * 2002-07-18 2002-08-28 Univ Bristol Detection of disease by analysis of emissions
TWI241912B (en) * 2002-10-30 2005-10-21 Food Industry Res & Dev Inst Novel Acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol
JP3648233B2 (en) * 2003-04-08 2005-05-18 明治飼糧株式会社 Feed composition
US20040258765A1 (en) * 2003-06-23 2004-12-23 Gee Gilbert C. Method for treatment of sores and lesions of the skin
FR2859217B1 (en) * 2003-09-03 2005-11-11 Rhodia Chimie Sa ACTIVATOR FOR FERMENTATION BASED ON LACTIC ACID BACTERIA AND PROCESS FOR PREPARING A PRODUCT USING SAID ACTIVATOR
GB0405540D0 (en) * 2004-03-11 2004-04-21 Glaxo Group Ltd Novel use
MY142017A (en) * 2004-03-19 2010-08-16 Nestec Sa Composition comprising all essential nutrients of a fruit or a plant material with increased stability and bioavailability and process of forming the same
US7344867B2 (en) * 2005-04-15 2008-03-18 Eamonn Connolly Selection and use of lactic acid bacteria for reducing inflammation in mammals
FR2889958A1 (en) * 2005-08-25 2007-03-02 Lyoct Sa Lab USE OF A SYMBIOTIC FOR THE TREATMENT OF ATOPIC DERMATITIS
KR100748846B1 (en) * 2006-12-29 2007-08-10 박일환 Preparation method of fermented propolis
SG10201506935QA (en) 2008-03-17 2015-10-29 Givaudan Sa Enzymatic process
ATE468761T1 (en) * 2008-06-11 2010-06-15 Ludwig Manfred Jacob FERMENTATION OF SOLUTIONS CONTAINING POMEGRANATE JUICE BY SACCHAROMYCES BOULARDII AND LACTOBACILLE, FERMENTATION PRODUCTS AVAILABLE THEREFROM AND THEIR USE
JP5584124B2 (en) * 2008-08-29 2014-09-03 明治飼糧株式会社 Anti-coccidial composition
WO2010096550A2 (en) 2009-02-18 2010-08-26 University Of Florida Research Foundation, Inc. Lactobacillus supplement for alleviating type 1 diabetes
US20120107291A1 (en) * 2009-06-19 2012-05-03 Danisco A/S Bifidobacteria for treating diabetes and related conditions
US20150320808A1 (en) * 2009-06-19 2015-11-12 Dupont Nutrition Biosciences Aps Bifidobacteria for treating cardiac conditions
KR101087973B1 (en) * 2009-06-30 2011-12-01 일동제약주식회사 Novel Lactobacillus helveticus, culture method thereof and use thereof
KR101297628B1 (en) * 2009-11-17 2013-08-19 농업회사법인 제주홍암가 주식회사 Food Composition for Diet
US8318215B1 (en) 2010-04-21 2012-11-27 Miriam Ryngler-Lewensztain Composition and method of preparing a tomato-based topical formulation for enhanced healing of burns, ultraviolet and radiation erythema
US9011909B2 (en) 2010-09-03 2015-04-21 Wisconsin Pharmacal Company, Llc Prebiotic suppositories
CN103820336A (en) 2010-11-12 2014-05-28 阿勒根公司 Metabolized conditioned growth medium and methods of use
FR2967333B1 (en) * 2010-11-17 2012-12-28 Pollenergie USE OF POLLEN AS AN ORAL NUTRITIONAL SUPPLEMENT TO PREVENT AND / OR COMBAT DENUTRITION
JP5667642B2 (en) * 2010-11-29 2015-02-12 株式会社明治 Endometriosis prevention and / or amelioration agent and food and beverage composition comprising the same
PL2648530T5 (en) 2010-12-07 2023-08-07 Purac Biochem B.V. Fruit ferments containing propionate and use thereof
CN102078354B (en) * 2011-01-21 2012-08-22 吉林紫鑫药物研究有限公司 Medicine composition capable of improving immunity and preparation method thereof
CN102078486B (en) * 2011-01-21 2012-06-20 吉林紫鑫药物研究有限公司 Drug composition for removing chloasma and preparation method thereof
US9504739B2 (en) 2011-03-01 2016-11-29 Quorum Innovations, Llc Method of identifying a biologically-active composition from a biofilm
US20140134705A1 (en) * 2011-06-23 2014-05-15 Rok Investment Group Limited Oil spill containment system and method
US20140328997A1 (en) * 2011-09-08 2014-11-06 Rutgers, The State University Of New Jersey Production of Enriched Products
WO2013155370A1 (en) * 2012-04-13 2013-10-17 The Regents Of The University Of California Sinusitis diagnostics and treatments
US10485258B2 (en) 2012-05-01 2019-11-26 Board Of Trustees, Rutgers, The State University Of New Jersey Production of enriched products
EP2664243A1 (en) * 2012-05-14 2013-11-20 Pollenergie Use of fresh mono-floral pollen for preventing and/or controlling malnutrition
US20140234259A1 (en) * 2012-12-11 2014-08-21 Suzanah Juras Natural Intra-Vaginal Inserts to Control Imbalanced pH
KR20160013069A (en) * 2013-05-10 2016-02-03 바이오위시 테크놀로지스, 인크. Compositions comprising a mixture of bacteria comprising pediococcus and lactobacillus and methods for decreasing the effects of alcohols
CN104187656A (en) * 2014-08-21 2014-12-10 席安胜 Dietary therapy formula aiming at gingivitis
US10045553B2 (en) 2014-12-18 2018-08-14 Mark H. Sterner Legume/grain based food product with prebiotic/probiotic source
US20160199425A1 (en) * 2015-01-08 2016-07-14 Nubiome, Inc. Treatment and Prophylaxis for Parkinson's Disease
EP3548045A1 (en) * 2016-11-30 2019-10-09 Probioswiss AG Urogenital medical device formulation based on suitable biochemical compositions for the stabilization of the acidity and the redox state of the vaginal fluid
US11464248B2 (en) 2017-11-03 2022-10-11 The Quaker Oats Company Co-fermented food product from dairy and grain
BR112020011999A2 (en) * 2017-12-14 2020-11-17 Pure Cultures 2020 Inc. probiotics and fermentation metabolites for the prevention and treatment of diseases and conditions in animals
CN110547420A (en) * 2018-05-30 2019-12-10 福州大学 Royal jelly enzyme buccal tablet and preparation method thereof
CN110547446A (en) * 2018-05-30 2019-12-10 福州大学 royal jelly antioxidant peptide fruit enzyme and preparation method thereof
CN110547447A (en) * 2018-05-30 2019-12-10 福州大学 Royal jelly collagen fruit enzyme and preparation method thereof
CN110547448A (en) * 2018-05-30 2019-12-10 福州大学 royal jelly collagen peptide fruit enzyme and preparation method thereof
AU2019100035A4 (en) * 2019-01-11 2019-03-07 Hu, Haiyan An antimicrobial strain composition and its preparation method
CN109757683B (en) * 2019-03-27 2022-03-29 海南百晋兴生物科技有限公司 Preparation method of whole-fruit citrus peel
CN111084310B (en) * 2019-12-30 2021-07-27 江南大学 Fermented beverage and preparation method thereof
WO2022167555A1 (en) * 2021-02-04 2022-08-11 Fermentationexperts A/S Feed comprising fermented sea-proteins
CN113519831B (en) * 2021-07-13 2022-04-29 江南大学 Fruit enzyme and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620877A (en) * 1993-03-26 1997-04-15 Arkenol, Inc. Method of fermenting sugars resulting from strong acid hydrolysis
WO1997029644A1 (en) * 1996-02-15 1997-08-21 Biotal Ltd. Microorganisms and their use in treating animal feed and silage
US6054148A (en) * 1997-12-19 2000-04-25 Board Of Trustees Operating Michigan State University Method and compositions for ensiling silage

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU291545A1 (en) 1969-03-28 1981-04-15 Пярнуский Комбинат Молочных Продуктов Method of producing forage for beas
US4110477A (en) * 1977-05-13 1978-08-29 Kabushiki Kaisha Naruse Fermentation Laboratory Method for producing natto containing lactic acid bacteria
JPS5592662A (en) * 1979-01-08 1980-07-14 Yoshihide Hagiwara Beverage made by lactic fermentation of adlay and method of making the same
US5340742A (en) * 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US5595892A (en) * 1991-12-20 1997-01-21 Shin-Etsu Chemical Co., Ltd. Process for preparation of purified xanthan gum
US5308615A (en) * 1992-01-17 1994-05-03 The United States Of America As Represented By The Secretary Of Agriculture Probiotic for control of Salmonella
KR950001449B1 (en) * 1992-07-03 1995-02-24 풀무원식품주식회사 Method of processing aloe
WO1994026133A1 (en) * 1993-05-11 1994-11-24 Otsuka Pharmaceutical Co., Ltd. Antioxidant food, antioxidant preparation and antioxidization method
US5587313A (en) * 1995-03-10 1996-12-24 University Of Maryland Method for fermentation of marine bacteria
US6046022A (en) * 1996-09-30 2000-04-04 Peking University Methods and compositions employing red rice fermentation products
US6030650A (en) * 1996-11-22 2000-02-29 Princeton Nutrition, L.L.C. Complete nutritional milk compositions and products
FR2756181B1 (en) * 1996-11-26 1999-03-05 Au Mont Beaute COSMETIC, PHARMACEUTICAL COMPOSITION BASED ON INACTIVE CULTURE OF BIFIDOBACTERIUM BACTERIA, MINT OIL AND AN ACID
IL130303A0 (en) 1999-06-03 2000-06-01 M G Novobiotech Ltd A bacterial strain processed plant extracts and probiotic compositions for human and veterinary use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620877A (en) * 1993-03-26 1997-04-15 Arkenol, Inc. Method of fermenting sugars resulting from strong acid hydrolysis
WO1997029644A1 (en) * 1996-02-15 1997-08-21 Biotal Ltd. Microorganisms and their use in treating animal feed and silage
US6054148A (en) * 1997-12-19 2000-04-25 Board Of Trustees Operating Michigan State University Method and compositions for ensiling silage

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210505A1 (en) * 2009-01-27 2010-07-28 Nestec S.A. Composition comprising caftaric acid and/or derivatives thereof
WO2010086331A3 (en) * 2009-01-27 2010-09-30 Nestec S.A. Composition comprising caftaric acid and/or derivatives thereof
CN102333459A (en) * 2009-01-27 2012-01-25 雀巢产品技术援助有限公司 The composition that comprises caffeoyl tartaric acid and/or its derivative
CN105192828A (en) * 2015-11-02 2015-12-30 广西金臣科技有限公司 Mango enzyme nutrient solution and preparation method thereof
CN113142451A (en) * 2021-05-12 2021-07-23 河北一然生物科技有限公司 Chinese herbal medicine fermentation inoculant and preparation method of fermented Chinese herbal medicine beverage

Also Published As

Publication number Publication date
US6953574B2 (en) 2005-10-11
US20080102061A1 (en) 2008-05-01
CA2484639C (en) 2012-01-24
US20030235559A1 (en) 2003-12-25
AU2003236536A1 (en) 2004-01-06
CA2484639A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
CA2484639C (en) Composition and method to produce and use fermented hydrolyzed products of miocrobial metabolism
KR100778886B1 (en) Preparation method of fermented fruits and vegetables, fermented fruits and vegetables prepared thereby and functional composition comprising the same
CN105167072B (en) A kind of production method of feature matrimony vine ferment and its product
CN103190626B (en) Fruit and vegetable food for treating oral ulcer and preparation method of fruit and vegetable food
JP4623896B2 (en) Bacterial strains, processed plant extracts and probiotic compositions used in humans and animals
CN105249100B (en) The production method of fermented fruits and vegetables juice and fermented glutinous rice beverage with compound functions
JP2003259835A (en) Production of fermented product and its utilization
EP3102670A1 (en) Systems, methods, and compositions relating to combiomics
CN108783431A (en) A kind of fruit ferment and preparation method thereof
CN112244286A (en) Calcium fruit powder and preparation method thereof
JP2009540861A (en) Method for producing powdered kimchi and kimchi composition produced thereby
CA2600118A1 (en) Fermented compositions having immunomodulatory actions
KR20160058389A (en) Method of Manufacturing Volumizing Antocyanine Probiotics Metabolite and Pharmetics, cosmetics and Juice and food complex
CN107530387B (en) Oral composition containing Bifidobacterium and cruciferous vegetable
CN108851045A (en) A kind of pectase and preparation method thereof
CN107874155A (en) A kind of fruity fermented vinegar egg chewable tablets and preparation method thereof
JP2000032909A (en) Food for improving digestion and absorption by environmental improvement caused by enteric microbe
CN108850667A (en) A kind of microorganism Remixed agent
Fouad et al. Bio-Labneh fortified with functional microcapsules filled with chickpea flour and probiotics
JP2010100663A (en) Enzyme inhibitor containing fermentation product of allium cepa l
JP2005097222A (en) Fermented product of allium cepa l.
KR100630337B1 (en) Process for preparing Opuntia ficus-indica fruit powder and milk product by fermentation
KR101945207B1 (en) Method for manufacturing a composition for enhancing intestinal environment and composition manufactured by the method
KR20170120264A (en) Fermented chestnut puree of probiotic lactic acid bacteria and foods composition, medicinal composition including the same
KR102217456B1 (en) Fermenting method for honey using microorganism, fermented honey manufactured by the same and products using thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2484639

Country of ref document: CA

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP